HotSpot Therapeutics, Inc., a Boston-based biotechnology company, announced on Wednesday that it is presenting its initial clinical data from the monotherapy dose-escalation portion of the Phase one study of HST-1011 in a Proffered Paper oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024, scheduled from 13 September to 17 September 2024, in Barcelona, Spain.

HST-1011 is an oral and selective inhibitor of Casitas B-lineage lymphoma proto-oncogene (CBL-B).

The clinical data is being revealed with a focus on safety, exposure, and pharmacodynamic measures.